ethyl chloroformyl acetate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: ethyl chloroformyl acetate
• 英文别名: Carbonochloridoyl butanoate
• 化学式: C₅H₇ClO₃
• 分子量: 150.562
• InChiKey: JCZSHFXMUOULJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl chloroformyl acetate 、 N-amino-4-methoxy-N'-phenylbenzenecarboximidamide 在 三乙胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 ethyl-5-(4-methoxyphenyl)-4-phenyl-4H-1,2,4-triazole-3-acetate
  参考文献：
  名称：

  4,5-Bis(aryl)-4H-1,2,4-triazole derivatives and analgesic use

  摘要：

  4H-1,2,4-三唑类新化合物的分子式为##STR1##其中R.sub.1、R.sub.2、R.sub.3和R.sub.4可以位于苯环的不同位置，分别选择自氢、--OH、1至4个碳原子的烷基、1至4个碳原子的烷氧基、卤素、--CF.sub.3、--NO.sub.2、--NH.sub.2和--NH--AlK和##STR2##以及AlK，AlK.sub.1和AlK.sub.2是1至4个碳原子的烷基，或者R.sub.1和R.sub.2一起和/或R.sub.3和R.sub.4一起是亚甲二氧基，R选择自氢、1至4个碳原子的烷基、--CH.sub.2 --COOH和--CH.sub.2 --COOAlK.sub.3，AlK.sub.3是1至4个碳原子的烷基，它们的无毒、药学上可接受的酸盐具有显著的镇痛活性，以及它们的制备新方法。

  公开号：

  US04512997A1

文献信息

• Carboxylic Acid Compounds and Use Thereof
  申请人：Inoue Teruhiko

  公开号：US20070197512A1

  公开（公告）日：2007-08-23

  Provision of a superior URAT1 activity inhibitor effective for the treatment and the like of a pathology involving uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urinary lithiasis, renal dysfunction, coronary heart disease, ischemic cardiac diseases and the like. A URAT1 activity inhibitor containing a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient: wherein each symbol is as defined in the specification.

  提供一种优越的URAT1活性抑制剂，用于治疗与尿酸有关的病理，如高尿酸血症、痛风石、急性痛风性关节炎、慢性痛风性关节炎、痛风性肾病、尿路结石、肾功能障碍、冠心病、缺血性心脏病等。 一种包含下式[1]所表示的化合物或其药学上可接受的盐，或其溶剂化合物的URAT1活性抑制剂作为活性成分： 其中每个符号如规范中定义。
• 2-Hydroxymethyl-thiazole-5-carboxylic acid derivatives
  申请人：Roussel-UCLAF

  公开号：US04001447A1

  公开（公告）日：1977-01-04

  Novel 2-hydroxymethyl-thiazole-5-carboxylic acid derivatives of the formula ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms, alkylcarbonyl of 2 to 5 carbon atoms, benzoyl, phenyl optionally substituted with at least one halogen and ##STR2## R.sub.1 and R.sub.2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 3 carbon atoms, Z is selected from the group of phenyl and phenoxy optionally substituted with at least one halogen and R' is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms and alkali metals, alkaline earth metals and aluminum salts, having a marked hypolipemiant activity as well as a clear vasodilatatory activity and which may possess hypocholesterolemiant activity and their preparation.

  2-羟甲基噻唑-5-羧酸衍生物的化学式为##STR1##其中R从氢、1至4个碳原子的烷基、2至5个碳原子的烷基羰基、苯甲酰、苯基（可选地取代至少一个卤素）和##STR2##中选择，R.sub.1和R.sub.2分别从氢和1至3个碳原子的烷基中选择，Z从苯基和苯氧基（可选地取代至少一个卤素）中选择，R'从氢和1至4个碳原子的烷基以及碱金属、碱土金属和铝盐中选择，具有显著的降脂作用以及清晰的扩血管作用，可能具有降胆固醇作用，以及它们的制备。
• PTERIN ANALOGS
  申请人：KAKKIS Emil D.

  公开号：US20100016328A1

  公开（公告）日：2010-01-21

  Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.

  本文披露了四氢生物黄素的类似物、包含类似物的组合物以及通过给予类似物治疗对四氢生物黄素敏感的病症的个体的方法。这些类似物可在目前使用四氢生物黄素治疗对四氢生物黄素疗法敏感的病症的任何地方使用。
• CARBOXYLIC ACID COMPOUND AND USE THEREOF
  申请人：Japan Tobacco, Inc.

  公开号：EP1985297A1

  公开（公告）日：2008-10-29

  Provision of a superior URAT1 activity inhibitor effective for the treatment and the like of a pathology involving uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urinary lithiasis, renal dysfunction, coronary heart disease, ischemic cardiac diseases and the like. A URAT1 activity inhibitor containing a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient: wherein each symbol is as defined in the specification.

  提供一种优异的URAT1活性抑制剂，有效治疗涉及尿酸的病症，如高尿酸血症、痛风性头痛、急性痛风性关节炎、慢性痛风性关节炎、痛风性肾、尿路结石、肾功能障碍、冠心病、缺血性心脏病等。 一种含有下式[1]代表的化合物或其药学上可接受的盐或其溶液作为活性成分的 URAT1 活性抑制剂： 其中各符号如说明书中所定义。
• FUSED-CYCLIC PYRAZOLONE FORMAMIDE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP3798218A1

  公开（公告）日：2021-03-31

  Provided are a class of fused-cyclic pyrazolone formamide compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided is a compound having the structure as shown in formula (I) (with each group defined in the description). The compound can be used as an AXL inhibitor in the preparation of a pharmaceutical composition for treating tumors.

  本发明提供了一类融合环状吡唑酮甲酰胺化合物及其制备方法、药物组合物和用途。具体而言，提供了一种具有如式（I）所示结构的化合物（各基团在描述中定义）。该化合物可作为AXL抑制剂用于制备治疗肿瘤的药物组合物。